Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6806127 in healthy male subjects
NCT02196636Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RO6806127 in schizophrenia (2 arms), sponsored by Roche. Primary endpoint: Incidence of adverse events at 21 days. Started Jul 2014; status: completed.
02
Drugs
RO6806127
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02196636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02196636.